We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Automated Third Generation Assay Determines Parathyroid Hormone Levels

By LabMedica International staff writers
Posted on 13 Jul 2011
A chemiluminescent immunoassay was released for the quantitative determination of parathyroid hormone (PTH) levels.

The new assay, dubbed Liaison1-84 PTH, determines PTH in serum and ethylenediaminetetraacetic acid (EDTA)-plasma, without cross-reactivity with the 7-84 PTH fragment.

An antibody, which is highly specific for the N-terminus of the peptide ensures 100% specificity for the whole PTH molecule and eliminates the problem of interference due to N-terminal fragments. More...
The Liaison1-84 PTH assay is therefore able to provide uniformity of results even in patients with kidney disease, who tend to accumulate these fragments in high concentrations.

DiaSorin (Turin, Italy) added the fully automated Liaison1-84 PTH assay to its bone and mineral panel, which includes Liaison 25-OH Vitamin D Total, Liaison N-TACT PTH, Liaison BAP Ostase, and Liaison Osteocalcin. The completed panel assesses and monitors bone metabolism diseases.

Related Links:

DiaSorin



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.